

Mark Berthold-Losleben

PhD, MD, MA

CURRENT POSITIONS

Since 05/2023

Senior Consultant Psychiatrist (50%) and Researcher (50%)

Ketamine Unit and Innovative Treatment Research, Østfold Hospital Trust, Moss, Norway

Since 10/2018

Associate Professor (20%)

Department of Mental Health, NTNU Norwegian University of Science and Technology, Trondheim, Norway

FORMER POSITIONS

09/2022 – 05/2023

Senior Consultant Psychiatrist, Acute Outpatient Care, Østfold Hospital Trust, Moss, Norway

09/2014 – 08/2022

Senior Consultant Psychiatrist, St. Olavs Hospital, Trondheim University Hospital, Norway

Acute Outpatient Care, Older Age Psychiatry, Inpatient Care

04/2020 – 05/2020

Guest Researcher, Carver College of Medicine, Department of Psychiatry, University of Iowa, USA

10/2018 – 09/2022

Leader of the Teaching Unit for Adult Psychiatry, Department of Mental Health

NTNU Norwegian University of Science and Technology, Trondheim, Norway

02/2008 – 04/2013 and 05/2014 – 07/2014

Resident in Psychiatry, RWTH University Hospital Aachen

Department of Psychiatry, Psychotherapy and Psychosomatics, Germany

05/2013 – 04/2014

Resident in Neurology, Medical Centre Aachen, Department of Neurology, Germany

04/2011 – 03/2013

Postdoc, RWTH University Hospital Aachen and Jülich Research Centre, Germany

01/2007 – 01/2008

Resident in Cardiology, Department of Cardiology, Robert-Koch-Hospital Gehrden, Germany

CURRENT RESEARCH PROJECTS

PreKET: Precision medicine approach to ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (EU CT number 2025-521330-29-00). **Role: National co-coordinating investigator and local PI.** Funded with NOK 24.9 millioner by KlinBeForsk.

The Role of Subjective Experience in Predicting Treatment Response to Intravenous Ketamine in Treatment-Resistant Depression. **Role: PhD main supervisor (and co-PI and local PI in the main project PreKET).** Funded with NOK 4 millioner from South-Eastern Norway Regional Health Authority (HSØ).

Empathy: An open-label, phase 2, proof of principle study of manualized MDMA-assisted therapy for young adults with treatment-resistant depression or persistent depressive disorder. **Role: Co-PI (and co-supervisor in the associated PhD project).** Funded with SEK 5 millioner by Norssken Mind and NOK 4 millioner from HSØ.

KetObs: Ketamine for treatment-resistant depression - A real-world observational study of predictors of treatment response and outcome. **Role: PhD main supervisor.** Funded with NOK 4 millioner by HSØ.

MAT-MDD: An Open-Label, Phase 2, Proof-of-Principle Study of Manualized MDMA-Assisted Therapy in Subjects with MDD. **Role: Project team member.** Funded with NOK 4 millioner by HSØ.

EXTERNAL FUNDING

Active contributor to successful external funding applications with a combined value of approximately NOK 42 millioner since 2024.

FORMER RESEARCH PROJECTS

- 2011 – 2013 *The effect of musical training on emotion regulation and neuronal plasticity*
Role: Postdoc. RWTH University Hospital and Jülich Research Centre, Germany
- 2011 – 2012 *Glucagon modulated connectivity and BOLD response*
Role: Study physician. RWTH University Hospital Aachen, Germany

RESEARCH GROUPS

- Leader **PsykForsk**, research group, Østfold Hospital Trust, Norway
- Member **NORAAD**, research network, Norway
- Member **Biological Psychiatry**, Department of Mental Health, NTNU, Norway
- Member **Psychedelic Research Group**, Innlandet Hospital Trust, Norway

CONTINUED EDUCATION

- 11/2023 **MDMA-assisted Therapy**, 5-day course in Iceland, organized by MAPS/Lycos/Resilient
- 2016 – 2018 **Cognitive Behavioral Analysis System of Psychotherapy (CBASP)**
Certified Therapist, Supervisor, and Trainer

EDUCATION

- 2008 Dr. med. / **PhD**, School of Medicine, Hannover, Germany
- 2006 Medicine / **MD**, School of Medicine, Hannover, Germany
- 2000 Master of Arts / **MA** in Religious Science, History, and Philosophy
University of Hannover, Germany
- 2000 Mathematics. No degree.

LANGUAGES

Norwegian, English, and German (mother tongue) fluent.